K. B. Nolop
- Immunology and Allergy top 0.5%
- Allergic Rhinitis and Sensitization 9
- Oncology top 0.5%
- Cutaneous Melanoma Detection and Management 8
- Cancer Research top 2%
- Molecular Biology top 2%
- Melanoma and MAPK Pathways 21
-
- Asthma and respiratory diseases 15
-
- Computational Drug Discovery Methods 9
-
- Inhalation and Respiratory Drug Delivery 8
- Respiratory Support and Mechanisms 7
- Respiratory and Cough-Related Research 7
- Co-authors
- Grant A. McArthurKeith T. FlahertyIgor PuzanovPaul B. ChapmanAntoni RibasJeffrey A. SosmanRichard J. LeeKevin B. Kim
- Journals
- Journal of Clinical Oncology (17 papers)Journal of Applied Physiology (6 papers)Annals of Allergy Asthma & Immunology (5 papers)
- Partner nations
- United StatesAustraliaUnited Kingdom
In The Last Decade
K. B. Nolop
64 papers receiving 7.1k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Immunology and Allergy 746
- Oncology 3.4k
- Cancer Research 908
- Molecular Biology 3.6k
- Pathology and Forensic Medicine 868
Countries citing papers authored by K. B. Nolop
This map shows the geographic impact of K. B. Nolop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. B. Nolop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. B. Nolop more than expected).
Fields of papers citing papers by K. B. Nolop
This network shows the impact of papers produced by K. B. Nolop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. B. Nolop. The network helps show where K. B. Nolop may publish in the future.
Co-authorship network
The 25 scholars most cited alongside K. B. Nolop, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancerbreakdown → | 2015 | 513 |
| 2 | Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studybreakdown → | 2015 | 433 |
| 3 | 2015 | 52 | |
| 4 | 2013 | 157 | |
| 5 | Vemurafenib: the first drug approved for BRAF-mutant cancerbreakdown → | 2012 | 594 |
| 6 | 2010 | 182 | |
| 7 | 2009 | 163 | |
| 8 | 2001 | 78 | |
| 9 | 2001 | 44 | |
| 10 | 2000 | 70 | |
| 11 | 1998 | 36 | |
| 12 | 1998 | 82 | |
| 13 | 1997 | 16 | |
| 14 | 1997 | 78 | |
| 15 | 1997 | 55 | |
| 16 | 1996 | 74 | |
| 17 | 1989 | 21 | |
| 18 | 1987 | 214 | |
| 19 | 1987 | 26 | |
| 20 | 1986 | 55 |
About K. B. Nolop
K. B. Nolop is a scholar working on Immunology and Allergy, Oncology and Sensory Systems, having authored 64 papers that have together received 7.3k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (21 papers), Asthma and respiratory diseases (15 papers), Allergic Rhinitis and Sensitization (9 papers), Computational Drug Discovery Methods (9 papers), Cutaneous Melanoma Detection and Management (8 papers), Inhalation and Respiratory Drug Delivery (8 papers), Respiratory Support and Mechanisms (7 papers) and Respiratory and Cough-Related Research (7 papers). The work is most often cited by research in Immunology and Allergy (746 citations), Oncology (3.4k citations) and Cancer Research (908 citations). K. B. Nolop has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Grant A. McArthur, Keith T. Flaherty, Igor Puzanov, Paul B. Chapman, Antoni Ribas, Jeffrey A. Sosman, Richard J. Lee, Kevin B. Kim, Peter J. O’Dwyer and Joseph F. Grippo. Their work appears in journals such as Journal of Clinical Oncology, Journal of Applied Physiology, Annals of Allergy Asthma & Immunology, Journal of Allergy and Clinical Immunology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.